A decision-making tool for first-line treatment in advanced non-small-cell lung cancer based on plasma proteome biomarkers

被引：0

作者：

Sela, Itamar

Christopoulos, Petros

Puzanov, Igor

Bar, Jair

Zer, Alona

Moskovitz, Mor

Reinmuth, Niels

Lotem, Michal

Katzenelson, Rivka

Agbarya, Abed

Farrugia, David

Price, Gillian

Cheley, Helen

Abu-Amana, Mahmud

McGregor, Kimberly

Lou, Yanyan

Leibowitz, Raya

Dicker, Adam P.

Carbone, David Paul

Gandara, David R.

机构：

[1] OncoHost LTD, Binyamina, Israel

[2] Heidelberg Univ Hosp, Heidelberg, Germany

[3] Roswell Pk Canc Inst, Buffalo, NY USA

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Rambam Hlth, Haifa, Israel

[6] Davidoff Canc Ctr, Rabin Med Ctr, Beilinson Campus, Petah Tiqwa, Israel

[7] Asklepios Clin Munich Gauting, Thorac Oncol, Gauting, Germany

[8] Hadassah Med Ctr, Jerusalem, Israel

[9] Kaplan Med Ctr, Dept Oncol, Rehovot, Israel

[10] Bnei Tzion Hosp, Haifa, Israel

[11] Gloucestershire Oncol Ctr, Cheltenham, England

[12] NHS Grampian, Aberdeen, Scotland

[13] Swansea Bay UHB, Swansea Bay, Wales

[14] Haemek Med Ctr, Afula, Israel

[15] OncoCyte, Cambridge, MA USA

[16] Mayo Clin, Jacksonville, FL USA

[17] Shamir Med Ctr, Beer Yaagov, Israel

[18] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA

[19] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[20] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9122

引用

页数：1

共 50 条

[31] First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer
Bearz, Alessandra
Passalacqua, Rodolfo
Alabiso, Oscar
Cinieri, Saverio
Gridelli, Cesare
Cravesana, Claudia
Crino, Lucio
CLINICAL DRUG INVESTIGATION, 2012, 32 (11) : 755 - 760
[32] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
Socinski, Mark A.
DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
[33] BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER IN CHINA
Zhang, Y.
Samuelsen, C. H.
Griebsch, I
Yao, Z.
VALUE IN HEALTH, 2018, 21 : S27 - S27
[34] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
Xin-Hua Xu
Jin Su
Xiang-Yang Fu
Feng Xue
Qiao Huang
Dao-Jun Li
Ming-Qian Lu
Cancer Chemotherapy and Pharmacology, 2011, 67 : 475 - 479
[35] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
Xu, Xin-Hua
Su, Jin
Fu, Xiang-Yang
Xue, Feng
Huang, Qiao
Li, Dao-Jun
Lu, Ming-Qian
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 475 - 479
[36] First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
Georgoulias, V
Androulakis, N
Dimopoulos, AM
Kourousis, C
Kakolyris, S
Papadakis, E
Apostolopoulou, F
Papadimitriou, C
Vossos, A
Agelidou, M
Heras, P
Tzannes, S
Vlachonicolis, J
Mavromanolakis, E
Hatzidaki, D
ANNALS OF ONCOLOGY, 1998, 9 (03) : 331 - 334
[37] How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
Peters, S.
Reck, M.
Smit, E. F.
Mok, T.
Hellmann, M. D.
ANNALS OF ONCOLOGY, 2019, 30 (06) : 884 - 896
[38] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
Olivier Bylicki
Helene Barazzutti
Nicolas Paleiron
Jacques Margery
Jean-Baptiste Assié
Christos Chouaïd
BioDrugs, 2019, 33 : 159 - 171
[39] Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
Engle, Jeff
Kolesar, Jill
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (22) : 1933 - 1938
[40] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Popat, Sanjay
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193

← 1 2 3 4 5 →